IGF-1 DES

IGF-1 DES, commonly referring to des(1-3)IGF-I, is an N-terminally truncated form of insulin-like growth factor 1 lacking the first three amino acids. The key research distinction is reduced binding to IGF-binding proteins, which can increase free receptor activity and potency in experimental systems. Most evidence is preclinical: cell culture studies, rodent growth models, and mechanistic work on IGF processing. It should not be conflated with mecasermin, the FDA-approved recombinant human IGF-1 drug for severe primary IGF-1 deficiency in children. Mecasermin's label provides useful safety context for IGF-1 pathway activation, but it does not establish safe or effective use of IGF-1 DES.

Binding-Protein Distinction

Des(1-3)IGF-I has reduced IGF-binding-protein binding and can be more potent than intact IGF-I in selected experimental systems ^[1].

Preclinical Growth and Cell Models

In lit/lit mouse models, des(1-3)IGF-I showed enhanced growth-promoting potency relative to IGF-I, and cell-culture work supports IGF receptor biology context ^[2][3].

Evidence Boundary

Direct clinical evidence for IGF-1 DES as a therapeutic, bodybuilding, recovery, or anti-aging product is lacking.

No Approved Human Indication

IGF-1 DES has no established approved human indication; do not extrapolate dosing or safety from mecasermin to unapproved IGF-1 analogs ^[5].

Growth and Metabolic Risks

Mecasermin labeling warns that IGF-1 therapy can cause severe hypoglycemia and is contraindicated with malignant neoplasia/history of malignancy and closed epiphyses, reflecting concerns around growth signaling ^[5].